Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mukherji

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
British Journal of Cancer|June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancerC Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology|January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancerC Pezaro, A Omlin, R Perez-Lopez, et al.
Clinical Radiology|September 23, 2015
Predictors of pneumothorax after CT-guided transthoracic needle lung biopsy: the role of quantitative CTH A Chami, W Faraj, Z A Yehia, et al.
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 4, 2021
Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and InterpretationA Fundytus, J C Wells, S Sharma, et al.
British Journal of Cancer|August 10, 2013
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancerA Omlin, C J Pezaro, S Zaidi, et al.
British Journal of Cancer|December 5, 2013
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'A Omlin, C J Pezaro, S Zaidi, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
ESMO Open|February 26, 2023
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee surveyH Linardou, A A Adjei, J Bajpai, et al.
ESMO Open|June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
British Journal of Cancer|June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancerC Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology|January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancerC Pezaro, A Omlin, R Perez-Lopez, et al.
Clinical Radiology|September 23, 2015
Predictors of pneumothorax after CT-guided transthoracic needle lung biopsy: the role of quantitative CTH A Chami, W Faraj, Z A Yehia, et al.
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 4, 2021
Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and InterpretationA Fundytus, J C Wells, S Sharma, et al.
British Journal of Cancer|August 10, 2013
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancerA Omlin, C J Pezaro, S Zaidi, et al.
British Journal of Cancer|December 5, 2013
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'A Omlin, C J Pezaro, S Zaidi, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
ESMO Open|February 26, 2023
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee surveyH Linardou, A A Adjei, J Bajpai, et al.
ESMO Open|June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Pageof 3